Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Sorafenib & Renal cell carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

FDA status

In the context of Sorafenib & Renal cell carcinoma (RCC), the FDA approved sorafenib for the treatment of patients with advanced renal cell carcinoma (RCC), based on the phase III TARGET trial in previously treated advanced RCC (2, 3).

EMA status

The EMA‑authorized sorafenib has an indication for patients with advanced renal cell carcinoma who have failed prior interferon‑alfa or [interleukin‑2‑based therapy](brain://KXRKhZG7dUyiAMJ6KTbBKQ/Interleukin2Il2RenalCellCar…

References (Sources)

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting
Fishman et al. 2015 PLoS One 10(4): e0120877
Review
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Eisen et al. 2020 JCO 38: 4064–4075
Sorafenib for the treatment of advanced renal cell carcinoma
Kane et al. 2006 Clin Cancer Res 12(24): 7271-8
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!